Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Q/C TECHNOLOGIES, INC.MYMD · Entity 7735 | Chief Legal Officer | August 24, 2023 | August 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Q/C TECHNOLOGIES, INC.
Report date August 24, 2023 · Filed August 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 400,000 |
Reported balance
After 2023-08-24 transaction · row 1
1 source rowRow 1 · 2023-08-24 · Purchase · Acquired 150,000 · Balance 400,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.15, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.15, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2023 Filed Aug 24, 2023 21:58 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | PurchaseCommon stock | 150,000 | $1.11 | $166,500.00 |
DisclosureSEC source: 0001493152-23-030111 · ownership.xml · nonDerivative · entry 1 Rivard Paul · CIK 0001857479 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.15, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 20:21 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | PurchaseCommon stock | 25,000 | $1.12 | $28,080.00 |
DisclosureSEC source: 0001493152-23-029445 · ownership.xml · nonDerivative · entry 1 Rivard Paul · CIK 0001857479 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 22:00 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001493152-23-020800 · ownership.xml · derivative · entry 1 Rivard Paul · CIK 0001857479 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 01:24 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | PurchaseCommon stock | 10,000 | $1.53 | $15,300.00 |
DisclosureSEC source: 0001493152-22-034969 · ownership.xml · nonDerivative · entry 1 Rivard Paul · CIK 0001857479 · EVP of Operations, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.53, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 17:56 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | PurchaseCommon stock | 15,000 | $6.03 | $90,450.00 |
DisclosureSEC source: 0001493152-21-029774 · ownership.xml · nonDerivative · entry 1 Rivard Paul · CIK 0001857479 · EVP of Operations, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.97 to $6.05, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 21:20 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantRestricted Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-025600 · ownership.xml · derivative · entry 1 Rivard Paul · CIK 0001857479 · EVP of Operations, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control. F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 01:44 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantStock Option (Right to Buy) · Derivative | 77,180 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001493152-21-009302 · ownership.xml · derivative · entry 2 Rivard Paul · CIK 0001857479 · EVP of Operations, GC 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 77,180 Underlying: Common Stock · 77,180 shares Expires 2023-04-16 F3 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share in connection with the Merger. F2 · derivative.exercise_date: These options are fully vested and exercisable. F4 · ownership.nature: These shares are jointly held by the reporting person and Jennifer Rivard as trustees for the Paul Rivard and Jennifer Rivard Revocable Living Trust. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 01:44 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantStock Option (Right to Buy) · Derivative | 77,180 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001493152-21-009302 · ownership.xml · derivative · entry 1 Rivard Paul · CIK 0001857479 · EVP of Operations, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,180 Underlying: Common Stock · 77,180 shares Expires 2023-04-16 F1 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share. F2 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.